MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET.
The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website. www.milestonepharma.com
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
704-803-9295
Investor Relations
Chris Calabrese
This email address is being protected from spambots. You need JavaScript enabled to view it.
Kevin Gardner
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.53 |
| Daily Change: | -1.03 -40.23 |
| Daily Volume: | 21,114,157 |
| Market Cap: | US$81.790M |
July 11, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
